[1] Whitehead, J. (1997) The Design and Analysis of Sequential Clinical Trials (2nd edition). John Wiley, Chichester.

[2] Ellenberg, S.S., and Hamiton, J.M. (1989) Surrogate endpoints in clinical trials: cancer. Statistics in Medicine, 8, 405-13.

[3] Prentice, R.L. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine, 8, 431-40.

[4] Buyse, M., Thirion, P., Carlson, R.W., Burzykowski, T., Molenberghs, G., and Piedbois, P. (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet, 356(9227), 373-8.

[5] Fleming, T.R. (1994) Surrogate markers in AIDS and cancer trials. Statistics in Medicine, 13, 1423-35.

[6] Karim, A.B.M.F., Afra, D., Cornu, P., Bleehen, N.M., Schraub, S., de Witte, O., Darcel, F., Stenning, S., Pierart, M., and Van Glabbeke, M. (2002) A randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: EORTC study 22845 with MRC study BR04 an interim analysis. International Journal of Radiation Oncology Biology Physics, 52(2), 316-24.

[7] Freedman, L.S. (1989) The size of clinical trials in cancer-research - what are the current needs. British Journal of Cancer, 59(3), 396-400.

[8] Freedman, L.S., and Speigelhalter, D.J. (1983) The assessment of subjective opinon and its use in relation to stopping rules for clinical trials. The Statistician, 32, 153-60.

[9] Saunders, M., Dische, S., Barrett, A., Harvey, A., Gibson, D., and Parmar, M. (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. Lancet, 350(9072), 161-5.

[10] Parmar, M.K.B., Griffiths, G.O., Spiegelhalter, D.J., Souhami, R.L., Altman, D.G., and der Scheuren, E. (2001) Monitoring of large randomized clinical trials: a new approach with Bayesian methods. Lancet, 358(9279), 375-81.

[11] Jones, W.G., Fossa, S.D., Mead, G.M., Roberts, J.T., Sokal, M., Naylor, S., and Stenning, S.P. (2001) A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18). European Journal of Cancer, 37(supp 6) abstract 572, S157.

[12] Gray, R., James, R., Mossman, J., and Stenning, S.P. (1991) Guest editorial: AXIS - A suitable case for treatment. British Journal of Cancer, 63, 841-5.

[13] The International Collaborative Ovarian Neoplasm (ICON) Group. (2002) Paclitaxel plus carbo-platin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360, 505-15.

[14] Mead, G.M., Bleehen, N.M., Gregor, A., Bullimore, J., Rampling, R., Roberts, J.T., Glaser, M., Lantos, P., Ironside, J.W., Moss, T.H., Brada, M., Whaley, J.B., and Stenning S.P. For the MRC Brain Tumour Working Party. (2000) A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer, 89(6), 1359-70.

[15] Shih, J.H. (1995) Sample size calculation for complex clinical trials with survival endpoints. Controlled Clinical Trials, 16(6), 395-407.

[16] Fleming, T.R. (1982) One sample multiple testing procedure for Phase II clinical trials. Biometrics, 38, 143-51.

[17] Gehan, E.A. (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases, 13, 346-53.

[18] Priestman, T.J., Bleehen, N.M., Rampling, R., Stenning, S.P., Nethersall, A.J., and Scott, J. (1993) A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma. Clinical Oncology, 5, 165-8.

[19] Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1-10.

[20] Machin, D., Campbell, M., Fayers, P., and Pinol, A. (1997) Sample Size Tables for Clinical Studies (2nd edition). Blackwell Science Ltd, Oxford, UK.

[21] De Wit, R., Louwerens, M., Mulder de, P.H.M., and Schornagel, J. (1998) A dose finding study of paclitaxel added to fixed doses of BEP in patients with adverse prognosis germ cell carcinoma of unknown primary (CUP). Proceedings of the American Society of Clinical Oncology, 17, 322.

[22] Freedman, L.S. (1982) Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine, 1, 121-9.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment